Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips
Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or...
MRNA drops 7% to $135 after a 392% YTD surge, as traders book profits with no new negative catalysts driving the decline.
Partner MRK gained 47% YTD on Keytruda's label expansion potential, while BNTX trails at 22% amid a slower oncology pivot and Moderna patent litigation.
Moderna's intismeran combined with Keytruda became the first positive phase 3 for an mRNA-based cancer therapy, targeting 112,000 new U.S. melanoma cases annually.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today .
Moderna ( NASDAQ:MRNA ) stock is down 7% to $135.22 in Monday morning trading, cooling off after one of the most explosive runs in biotech this year. The pullback follows a vertical ascent that carried shares to a record high of $176.66 during last week's advance. Volume has been heavy since the opening bell as short-term traders lock in gains.
The give-back looks orderly. Moderna stock was up 392% year to date (YTD) through Friday's close, so a single-session dip of this size still leaves the run largely intact. That proportion is the story here. For context, the iShares Biotechnology ETF ( NASDAQ:IBB ) is down 1% to $211.73.
Reddit sentiment on Moderna remained very bullish through the weekend even as the drawdown developed, suggesting the retail base has not turned. Institutional positioning is the swing factor.
No new company announcement, trial update, regulatory action or analyst downgrade has been reported today. The phase 3 melanoma data that fueled the rally is unchanged, and Moderna hasn't disclosed material news since its July 31 second-quarter report. Traders are simply booking gains after a parabolic move.
Options positioning reinforces the read. The put-call ratio across Moderna's full chain sits at 1.06, with heavier hedging visible in longer-dated 2027 expirations. That skew is consistent with holders locking in profits and buying downside protection.
Melanoma Data Still Anchors the Bull Case
The catalyst behind the rally remains intact. Moderna's intismeran autogene, an mRNA-based individualized neoantigen therapy, was tested in combination with Merck 's ( NYSE:MRK ) Keytruda in a late-stage melanoma trial, and at a pre-specified interim analysis the combination met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival.
Gathered from external sources. Rights to this text belong to whoever originally published it.